Sarepta Therapeutics Inc
SRPT21.245USD
+0.205+0.97%
交易中 （美东）报价延迟15分钟
2.23B总市值
亏损市盈率 TTM
关于 Sarepta Therapeutics Inc 公司
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Sarepta Therapeutics Inc简介
公司代码SRPT
公司名称Sarepta Therapeutics Inc
上市日期Jun 04, 1997
CEOIngram (Douglas S)
员工数量1372
证券类型Ordinary Share
年结日Jun 04
公司地址215 First Street
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02142
电话16172744000
网址https://www.sarepta.com/
公司代码SRPT
上市日期Jun 04, 1997
CEOIngram (Douglas S)
Sarepta Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
929.39K
+138.12%
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
196.90K
-2.27%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
189.46K
+315.61%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
136.04K
-0.12%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Ms. Cristin L. Rothfuss
Ms. Cristin L. Rothfuss
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
--
--
Ms. Deirdre Connelly
Ms. Deirdre Connelly
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
929.39K
+138.12%
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
196.90K
-2.27%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
189.46K
+315.61%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
136.04K
-0.12%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
业务USD
名称
营收
占比
ELEVIDYS
281.85M
54.93%
PMO Products
231.27M
45.07%
collaboration and other
97.97M
19.09%
地区USD
名称
营收
占比
United States
484.77M
94.48%
Rest of World
28.35M
5.52%
业务
地区
业务USD
名称
营收
占比
ELEVIDYS
281.85M
54.93%
PMO Products
231.27M
45.07%
collaboration and other
97.97M
19.09%
股东统计
更新时间: 11月21日 周五
更新时间: 11月21日 周五
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
11.00%
The Vanguard Group, Inc.
10.30%
State Street Investment Management (US)
5.06%
Two Sigma Investments, LP
3.91%
Barry (Richard J)
3.07%
其他
66.67%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
11.00%
The Vanguard Group, Inc.
10.30%
State Street Investment Management (US)
5.06%
Two Sigma Investments, LP
3.91%
Barry (Richard J)
3.07%
其他
66.67%
股东类型
持股股东
占比
Investment Advisor
38.36%
Investment Advisor/Hedge Fund
21.36%
Hedge Fund
15.76%
Research Firm
6.32%
Individual Investor
5.16%
Pension Fund
1.40%
Sovereign Wealth Fund
0.90%
Bank and Trust
0.69%
Family Office
0.07%
其他
9.97%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
1019
84.30M
80.53%
-21.85M
2025Q2
1032
95.91M
98.15%
-10.95M
2025Q1
1077
102.36M
104.40%
-6.43M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
2023Q3
916
88.86M
95.27%
-4.43M
2023Q2
931
87.46M
93.91%
-4.38M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
9.84M
9.4%
+937.08K
+10.53%
Jun 30, 2025
The Vanguard Group, Inc.
10.64M
10.17%
+1.51M
+16.51%
Aug 29, 2025
State Street Investment Management (US)
4.70M
4.49%
+626.55K
+15.40%
Jun 30, 2025
Two Sigma Investments, LP
4.15M
3.96%
+3.31M
+397.77%
Jun 30, 2025
Barry (Richard J)
3.21M
3.07%
+32.60K
+1.02%
May 16, 2025
Erste Asset Management GmbH
1.62M
1.55%
+560.35K
+52.81%
Jun 30, 2025
D. E. Shaw & Co., L.P.
5.06M
4.83%
+581.27K
+12.98%
Jul 18, 2025
abrdn Inc.
1.24M
1.19%
+592.13K
+91.06%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Neuroscience and Healthcare ETF
3.74%
First Trust NYSE Arca Biotechnology Index Fund
3.65%
Invesco Biotechnology & Genome ETF
3.49%
Invesco S&P SmallCap Health Care ETF
1.44%
Global X Genomics & Biotechnology ETF
1.39%
Invesco S&P SmallCap 600 Pure Growth ETF
1.32%
Virtus LifeSci Biotech Products ETF
1.03%
State Street SPDR S&P Biotech ETF
1.03%
Direxion Daily S&P Biotech Bull 3X Shares
0.63%
First Trust Health Care Alphadex Fund
0.51%
查看更多
iShares Neuroscience and Healthcare ETF
占比3.74%
First Trust NYSE Arca Biotechnology Index Fund
占比3.65%
Invesco Biotechnology & Genome ETF
占比3.49%
Invesco S&P SmallCap Health Care ETF
占比1.44%
Global X Genomics & Biotechnology ETF
占比1.39%
Invesco S&P SmallCap 600 Pure Growth ETF
占比1.32%
Virtus LifeSci Biotech Products ETF
占比1.03%
State Street SPDR S&P Biotech ETF
占比1.03%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.63%
First Trust Health Care Alphadex Fund
占比0.51%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Sarepta Therapeutics Inc的前五大股东是谁？
Sarepta Therapeutics Inc 的前五大股东如下：
BlackRock Institutional Trust Company, N.A.持有股份：9.84M，占总股份比例：9.40%。
The Vanguard Group, Inc.持有股份：10.64M，占总股份比例：10.17%。
State Street Investment Management (US)持有股份：4.70M，占总股份比例：4.49%。
Two Sigma Investments, LP持有股份：4.15M，占总股份比例：3.96%。
Barry (Richard J)持有股份：3.21M，占总股份比例：3.07%。
BlackRock Institutional Trust Company, N.A.持有股份：9.84M，占总股份比例：9.40%。
The Vanguard Group, Inc.持有股份：10.64M，占总股份比例：10.17%。
State Street Investment Management (US)持有股份：4.70M，占总股份比例：4.49%。
Two Sigma Investments, LP持有股份：4.15M，占总股份比例：3.96%。
Barry (Richard J)持有股份：3.21M，占总股份比例：3.07%。
Sarepta Therapeutics Inc的前三大股东类型是什么？
Sarepta Therapeutics Inc 的前三大股东类型分别是：
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
有多少机构持有Sarepta Therapeutics Inc(SRPT)的股份？
截至2025Q3，共有1019家机构持有Sarepta Therapeutics Inc的股份，合计持有的股份价值约为84.30M，占公司总股份的80.53%。与2025Q2相比，机构持股有所增加，增幅为-17.61%。
哪个业务部门对Sarepta Therapeutics Inc的收入贡献最大？
在FY2025Q2，ELEVIDYS业务部门对Sarepta Therapeutics Inc的收入贡献最大，创收281.85M，占总收入的54.93%。
